Loading company
vTv Therapeutics Inc.
VTVT · Nasdaq · ·
Next earnings: November 5, 2026
$30.01-2.5%Sep 29 close
- 1M
- -7.3%
- 6M
- -18.2%
- 1Y
- +28.5%
- 5Y
- -56.4%
VTVT · Nasdaq · ·
Next earnings: November 5, 2026
$30.01-2.5%Sep 29 close
vTv Therapeutics Inc. is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $0.00 | $0.00 | — |
| Profit | -$13.1M | -$6M | -115.91% |
| Free Cash Flow | -$2.9M | -$6.4M | +54.59% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
vTv Therapeutics Inc. has no earnings call transcript available.
“Cadisegliatin has been specifically designed to address the significant unmet need of hypoglycemia, a major limiting factor in achieving optimal blood glucose control in T1D,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
Cadisegliatin (TTP399) is a novel, oral small molecule, liver-selective glucokinase activator being investigated in the U.S. as a potential first-in-class oral adjunctive treatment for T1D. In non-clinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently from insulin. These studies support clinical investigation of whether c adisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA). Cadisegliatin is under investigation, and the safety and efficacy have not been established. There is no guarantee that this product will receive health authority approval or become commercially available for the use being investigat ed.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from vTv Therapeutics Inc.’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.